Q-omics provides the consensus-scored FBRSL1 profile across patient tissues and cancer cell-line models. FBRSL1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, FBRSL1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FBRSL1 RNA expression shows 20,141 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where FBRSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBRSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBRSL1 survival associations across molecular data types. FBRSL1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBRSL1 RNA expression–survival associations across cancer types. High FBRSL1 expression shows unfavorable associations in ACC, SKCM, KICH, LIHC and KIRC, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for FBRSL1 RNA expression.
This table summarizes FBRSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBRSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBRSL1 shows higher tumor expression in HNSC, COAD, LIHC, LUSC, STAD and CHOL. The HNSC box plot shows higher FBRSL1 RNA expression in tumor versus normal tissue (log2 FC = +1.014, t-test p < 0.001).
This table shows molecular features associated with FBRSL1 in patient tissues and cancer cell lines. In patient samples, FBRSL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBRSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
